

Andrew J Cooper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7671944/publications.pdf>

Version: 2024-02-01

10
papers

42
citations

1936888

4
h-index

1872312

6
g-index

10
all docs

10
docs citations

10
times ranked

52
citing authors

#	ARTICLE	IF	CITATIONS
1	Type 2 diabetes and heart failure: insights from the global DISCOVER study. ESC Heart Failure, 2021, 8, 1711-1716.	1.4	10
2	Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. Diabetes, Obesity and Metabolism, 2021, 23, 1956-1960.	2.2	8
3	What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin ($\geq 7.0\%$) at initiation of second-line therapy? Results from the DISCOVER study. Diabetes, Obesity and Metabolism, 2021, 23, 2336-2343.	2.2	6
4	Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study. BMJ Open Diabetes Research and Care, 2021, 9, e001585.	1.2	4
5	Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2022, 185, 109218.	1.1	4
6	Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study. Diabetes Research and Clinical Practice, 2021, 178, 108947.	1.1	3
7	Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2021, 180, 108974.	1.1	3
8	324-OR: Global Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: Results from DISCOVER. Diabetes, 2021, 70, 324-OR.	0.3	2
9	1598-P: HbA1c $\leq 7.0\%$ 6 Months after Initiation of Second-Line Therapy in Patients with Uncontrolled Type 2 Diabetes Is Associated with Good Glycemic Control at 3 Years: The DISCOVER Study. Diabetes, 2020, 69, .	0.3	2
10	1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study. Diabetes, 2020, 69, .	0.3	0